Neuropediatrics 2013; 44(05): 281-285
DOI: 10.1055/s-0033-1338133
Short Communication
Georg Thieme Verlag KG Stuttgart · New York

3-Phosphoglycerate Dehydrogenase Deficiency: Description of Two New Cases in Tunisia and Review of the Literature

Ichraf Kraoua
1   Department of Child and Adolescent Neurology and UR 06/11, National Institute Mongi Ben Hmida of Neurology, Tunis, Tunisia
,
Elsa Wiame
2   Christian de Duve Institute, Université Catholique de Louvain (UCL), Brussels, Belgium
,
Lilia Kraoua
3   Department of Genetics, Charles Nicolle Hospital, Tunis, Tunisia
,
Fehmi Nasrallah
4   Laboratory of Biochemistry, La Rabta Hospital, Tunis, Tunisia
,
Hanen Benrhouma
1   Department of Child and Adolescent Neurology and UR 06/11, National Institute Mongi Ben Hmida of Neurology, Tunis, Tunisia
,
Aida Rouissi
1   Department of Child and Adolescent Neurology and UR 06/11, National Institute Mongi Ben Hmida of Neurology, Tunis, Tunisia
,
Ilhem Turki
1   Department of Child and Adolescent Neurology and UR 06/11, National Institute Mongi Ben Hmida of Neurology, Tunis, Tunisia
,
Habiba Chaabouni
3   Department of Genetics, Charles Nicolle Hospital, Tunis, Tunisia
,
Gilbert Briand
5   Laboratory of Biochemistry and Molecular Biology, University Hospital of Lille, Lille, France
,
Naziha Kaabachi
4   Laboratory of Biochemistry, La Rabta Hospital, Tunis, Tunisia
,
Emile Van Schaftingen
2   Christian de Duve Institute, Université Catholique de Louvain (UCL), Brussels, Belgium
,
Neziha Gouider-Khouja
1   Department of Child and Adolescent Neurology and UR 06/11, National Institute Mongi Ben Hmida of Neurology, Tunis, Tunisia
› Author Affiliations
Further Information

Publication History

29 October 2012

28 January 2013

Publication Date:
06 April 2013 (online)

Abstract

3-Phosphoglycerate dehydrogenase (3-PGDH) deficiency is a rare autosomal recessive disorder of serine biosynthesis. It is typically characterized by congenital microcephaly, intractable seizures of infantile onset, and severe psychomotor retardation. Diagnosis is suspected on decreased l-serine levels in plasma and cerebrospinal fluid (CSF) and confirmed by genetic study. Early diagnosis in index cases allows supplementation in serine and prevention of fixed lesions. Prenatal diagnosis and genetic counseling allows prevention of secondary cases. We report on the two first unrelated Tunisian families with 3-PGDH deficiency confirmed by biochemical and genetic study. We discuss clinical, biochemical, imaging, electroencephalographic, and therapeutic aspects and review the literature.

 
  • References

  • 1 de Koning TJ, Klomp LW. Serine-deficiency syndromes. Curr Opin Neurol 2004; 17 (2) 197-204
  • 2 Jaeken J, Detheux M, Van Maldergem L, Foulon M, Carchon H, Van Schaftingen E. 3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis. Arch Dis Child 1996; 74 (6) 542-545
  • 3 de Koning TJ, Duran M, Dorland L , et al. Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency. Ann Neurol 1998; 44 (2) 261-265
  • 4 Pineda M, Vilaseca MA, Artuch R , et al. 3-phosphoglycerate dehydrogenase deficiency in a patient with West syndrome. Dev Med Child Neurol 2000; 42 (9) 629-633
  • 5 Klomp LWJ, de Koning TJ, Malingré HEM , et al. Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency—a neurometabolic disorder associated with reduced L-serine biosynthesis. Am J Hum Genet 2000; 67 (6) 1389-1399
  • 6 Häusler MG, Jaeken J, Mönch E, Ramaekers VT. Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings. Neuropediatrics 2001; 32 (4) 191-195
  • 7 Pind S, Slominski E, Mauthe J , et al. V490M, a common mutation in 3-phosphoglycerate dehydrogenase deficiency, causes enzyme deficiency by decreasing the yield of mature enzyme. J Biol Chem 2002; 277 (9) 7136-7143
  • 8 de Koning TJ. Treatment with amino acids in serine deficiency disorders. J Inherit Metab Dis 2006; 29 (2–3) 347-351
  • 9 Coşkun T, Aydin HI, Kiliç M , et al. 3-phosphoglycerate dehydrogenase deficiency: a case report of a treatable cause of seizures. Turk J Pediatr 2009; 51 (6) 587-592
  • 10 De Koning TJ, Duran M, Van Maldergem L , et al. Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids. J Inherit Metab Dis 2002; 25 (2) 119-125
  • 11 de Koning TJ, Jaeken J, Pineda M, Van Maldergem L, Poll-The BT, van der Knaap MS. Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency. Neuropediatrics 2000; 31 (6) 287-292
  • 12 Tabatabaie L, Klomp LW, Rubio-Gozalbo ME , et al. Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency. J Inherit Metab Dis 2011; 34 (1) 181-184
  • 13 Méneret A, Wiame E, Marelli C, Lenglet T, Van Schaftingen E, Sedel F. A serine synthesis defect presenting with a Charcot-Marie-Tooth-like polyneuropathy. Arch Neurol 2012; 69 (7) 908-911
  • 14 Tabatabaie L, de Koning TJ, Geboers AJJM, van den Berg IET, Berger R, Klomp LWJ. Novel mutations in 3-phosphoglycerate dehydrogenase (PHGDH) are distributed throughout the protein and result in altered enzyme kinetics. Hum Mutat 2009; 30 (5) 749-756
  • 15 de Koning TJ, Klomp LWJ, van Oppen AC , et al. Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency. Lancet 2004; 364 (9452) 2221-2222